Drug Trial Radar · NCT06177912
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
882
Actual
Start
Jan 18, 2024
Primary completion
Feb 26, 2025
Study completion Feb 26, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as infants/toddlers. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting pneumococcal disease (PD).
Conditions
- Pneumococcal Infection
Interventions
V116Biological
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
PPSV23Biological
Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Solicited Injection-site Adverse Events (AEs)Time frame: Up to 5 days postvaccination
- Percentage of Participants With Solicited Systemic AEsTime frame: Up to 5 days post vaccination
- Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)Time frame: Up to approximately 6 months
- Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA) ResponsesTime frame: 30 days postvaccination
Locations
92 sites in 13 countries. Site status is shown where the registry gives one.
Central Research Associates ( Site 0145)
Birmingham, Alabama
Velocity Clinical Research, Phoenix ( Site 0122)
Phoenix, Arizona
Madera Family Medical Group ( Site 0120)
Madera, California
Optumcare Colorado Springs, LLC ( Site 0113)
Colorado Springs, Colorado
Accel Research Sites Network- Nona Pediatric Center ( Site 0109)
Orlando, Florida
University of South Florida-Department of Pediatrics ( Site 0110)
Tampa, Florida
Velocity Clinical Research at Primary Pediatrics, Macon ( Site 0128)
Macon, Georgia
Bingham Memorial Hospital ( Site 0149)
Blackfoot, Idaho
Clinical Research Prime ( Site 0105)
Idaho Falls, Idaho
Clinical Research Prime Rexburg ( Site 0104)
Rexburg, Idaho
University of Louisville, Norton Children's Research Institute ( Site 0148)
Louisville, Kentucky
Velocity Clinical Research, Lafayette ( Site 0103)
Lafayette, Louisiana
Velocity Clinical Research, Gulfport ( Site 0115)
Gulfport, Mississippi
Velocity Clinical Research, Hastings ( Site 0114)
Hastings, Nebraska
Midwest Children's Health Research Institute ( Site 0117)
Lincoln, Nebraska
Midwest Children's Health Research Institute ( Site 0106)
Lincoln, Nebraska
Midwest Children's Health Research Institute-Research ( Site 0119)
Lincoln, Nebraska
Midwest Children's Health Research Institute-Research ( Site 0102)
Lincoln, Nebraska
Velocity Clinical Research, Albuquerque ( Site 0112)
Albuquerque, New Mexico
Velocity Clinical Research, Vestal ( Site 0121)
Vestal, New York
Epic Medical Research - Oklahoma ( Site 0134)
Chickasha, Oklahoma
Tribe Clinical Research, LLC-Pediatrics ( Site 0118)
Greenville, South Carolina
Tribe Clinical Research - Spartanburg ( Site 0108)
Spartanburg, South Carolina
Velocity Clinical Research, Austin ( Site 0129)
Austin, Texas
PanAmerican Clinical Research ( Site 0132)
Brownsville, Texas
Epic Medical Research ( Site 0133)
DeSoto, Texas
Epic Medical Research - Mesquite ( Site 0144)
Mesquite, Texas
Alliance for Multispecialty Research, LLC ( Site 0140)
Layton, Utah
Velocity Clinical Research, Salt Lake City ( Site 0124)
West Jordan, Utah
Canadian Center for Vaccinology ( Site 0004)
Halifax, Nova Scotia, Canada
Premier Clinical Trial Network ( Site 0008)
Hamilton, Ontario, Canada
Children's Hospital of Eastern Ontario ( Site 0001)
Ottawa, Ontario, Canada
CHU Sainte-Justine ( Site 0007)
Montreal, Quebec, Canada
McGill University Health Centre - Vaccine Study Centre ( Site 0005)
Pierrefonds, Quebec, Canada
CHU de Québec-Université Laval ( Site 0006)
Québec, Quebec, Canada
Hospital Dr. Hernán Henríquez Aravena ( Site 0208)
Temuco, Araucania, Chile
Centro de Estudios Clínicos (ICIM, Facultad de Medicina Clínica Alemana Universidad del Desarrollo)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile-Pediatric Infectious Diseases and Immunology ( Site 0209)
Santiago, Region M. de Santiago, Chile
Hospital Roberto del Río-Infectología Pediátrica ( Site 0200)
Santiago, Region M. de Santiago, Chile
Hospital Padre Hurtado-NEONATOLOGY/PEDIATRICS ( Site 0204)
Santiago, Region M. de Santiago, Chile
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.